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Abstract  
Objectives: A uniform rationalized management protocol for pregnancies of unknown 
location (PUL) is lacking. We developed a two-step triage protocol based on 
presenting serum progesterone (step 1) and hCG ratio two days later (step 2) to select 
PUL at high-risk of ectopic pregnancy (EP). 
 
Methods: Cohort study of 2753 PUL (301 EP), involving a secondary analysis of 
prospectively and consecutively collected PUL at two London-based university 
teaching hospitals. Using a chronological split we used 1449 PUL for development 
and 1304 for validation. We aimed to select PUL as low-risk with high confidence 
(high negative predictive value, NPV) while classifying most EP as high-risk (high 
sensitivity). The first triage step selects low-risk PUL at presentation using a serum 
progesterone threshold. The remaining PUL are triaged using a novel logistic 
regression risk model based on hCG ratio and initial serum progesterone (second step), 
defining low-risk as an estimated EP risk <5%. 
 
Results: On validation, initial serum progesterone ≤2nmol/l (step 1) selected 16.1% 
PUL as low-risk. Second step classification with the risk model ‘M6P’ selected an 
additional 46.0% of all PUL as low-risk. Overall, the two-step protocol classified 
62.1% of PUL as low-risk, with an NPV of 98.6% and a sensitivity of 92.0%. When 
the risk model was used in isolation (i.e. without the first step), 60.5% of PUL were 
classified as low-risk with 99.1% NPV and 94.9% sensitivity.  
 
Conclusions: The two-step protocol can efficiently classify PUL into being at high or 
low risk of complications. 
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Introduction  
 
Pregnancy of unknown location (PUL) describes a woman who has a positive 
pregnancy test without evidence of a pregnancy inside or outside the endometrial 
cavity using transvaginal sonography (TVS). The management of PUL can be 
prolonged, costly and lacks uniformity. The serum biomarkers human chorionic 
gonadotrophin (hCG)1-4 and/or progesterone5-7 are used to guide management. PUL 
prediction now focuses on triaging PUL as low-risk or high-risk of complications.8-13 
Low-risk implies the final outcome is an intrauterine pregnancy (IUP) or a failed PUL 
(FPUL), high-risk that the final outcome is an ectopic pregnancy (EP) or persistent 
PUL (PPUL). Risk stratification allows resources to be rationalized so women with 
low-risk PUL avoid unnecessary additional blood tests, visits to hospital and 
ultrasound scans whilst focusing resources on high-risk PUL that are at greater risk of 
potentially life-threatening EP. For this streamlining of resources to be safe, the 
classification tool used to determine risk must be accurate, particularly regarding the 
classification of EP. Inevitably some EP will be misclassified as low-risk, but many 
are likely to resolve without harm, especially if they are associated with low initial 
progesterone or declining hCG values.  
  
In a multi-center study on 1962 PUL, Van Calster et al14 externally validated the 
performance of the ‘M4’ model, a logistic regression model utilizing the initial hCG 
and hCG ratio. Based on a risk of EP <5%, M4 classified 70% PUL as low-risk, with 
97% being an FPUL/IUP. Eighty-eight percent of EP were correctly classified as 
high-risk. Although triage based on single progesterone has good results5,6, M4-based 
triage outperforms hCG ratio or serum progesterone cut-offs.15 Previous work 
suggested that clinical symptoms do not meaningfully improve prediction.16 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
 
To avoid unnecessary visits and blood tests, the interpretation of serum hormone 
levels used to manage PUL needs standardizing. Our previously published M4 model 
was developed on a relatively small number of PUL and required a minimum of two 
visits. The aim of the current study was to develop a novel two-step protocol, 
combining both the initial serum progesterone level and hCG ratio, that is developed 
on a much larger cohort of PUL and allows discharge of some PUL after just one visit. 
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Methods 
 
Design, setting and participants 
This observational cohort study for diagnostic accuracy involves a secondary analysis 
of data from the early pregnancy assessment units (EPAU) at two London-based 
university teaching hospitals: St Georges’ (SGH) and Queen Charlottes’ & Chelsea 
(QCCH). Women attend EPAUs up to 12 weeks gestation and are either 
asymptomatic and undergo ultrasonography for reassurance or present with symptoms 
such as pain, bleeding and/or hyperemesis. Data on consecutive women with a PUL 
was prospectively collected from July 2003 to February 2007 at SGH and April 2009 
to December 2013 at QCCH using a standardized protocol8,12. We excluded women 
known to be on progesterone supplementation and those with initial hCG ≤25IU/L, 
because this is the cut-off at which most urine pregnancy tests would be negative and 
the majority of clinicians in this study did not bring these PUL back for a 48 hour 
hCG level but a urine pregnancy test in two weeks to confirm a repeat negative result. 
The data were divided into a development dataset and a temporal validation dataset 
using a chronologic split within each center. As the normal clinical management of 
patients was not changed, data collection was registered as an audit at Imperial 
College Healthcare NHS trust. We followed the recently published TRIPOD 
(Transparent reporting of a multivariable prediction model for individual prognosis or 
diagnosis) guidelines when preparing this report.17 
 
Data collection  
Immediately following identification of a PUL, women had blood samples taken for 
measurement of serum progesterone and hCG as a part of routine clinical 
management provided at SGH and QCCH. Patients had the serum hCG measurement 
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repeated approximately 48 hours later. At QCCH, blood samples were separated 
within one hour and assayed using the Abbott progesterone and hCG assays run 
onboard the Abbott Architect i2000SR instrument (Abbott Laboratories, Abbott Park, 
IL).  The Architect progesterone assay is a one-step, competitive, single-site type 
immunoassay that uses chemiluminescent paramagnetic microparticle immunoassay 
(CMIA ‘ChemiflexTM technology’). The analytical sensitivity of the assay is ≤0.1 µg/l, 
has a precision of <10% (total interassay CV) and <5% cross-reactivity across a range 
of over forty tested cholesterol-derived molecules.  The Architect hCG assay is a two-
step, non-competitive, two-site type immunoassay that employs two mouse 
monoclonal antibodies and CMIA ‘ChemiflexTM technology’. The analytical 
sensitivity of the assay is ≤1.2 IU/L, has a precision of <10% (total interassay CV) 
and <10% cross-reactivity with FSH, LH and TSH. At SGH, blood samples were 
separated within one hour and assayed using the Roche (Basel, Switzerland) Elecsys 
E180 immunoassay analyzer. The Roche progesterone assay (Elecsys 2010 
progesterone II) is a one-step, competitive, single-site type immunoassay that uses an 
electrochemiluminescent paramagnetic microparticle immunoassay (ECL technology). 
The analytical sensitivity of the assay is 0.48 nmol/l, has a precision of <10% (total 
interassay CV) and <5% cross-reactivity across a range of >40 tested cholesterol-
derived molecules. The Roche HCG+β assay (Elecsys 2010) is a two-step, non-
competitive, two-site type immunoassay that employs a mouse monoclonal antibody 
and streptavidin-coated paramagnetic microparticle immunoassay system. The 
analytical sensitivity of the assay is < 0.6 mIU/mL, has a precision of <10% (total 
interassay CV) and <5% cross-reactivity with TSH, LH and FSH. The two units, 
therefore, had assays with similar performance characteristics. 
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All samples were processed and tested in accordance with standard medical 
laboratory practice including daily analysis of QC samples to check assay accuracy, 
precision and further procedures as specified by Clinical Pathology Accreditation 
(CPA) quality standards. 
 
Reference standard: pregnancy outcome definitions 
Pregnancies were followed up until the final clinical outcome was known. This was 
either an FPUL, IUP, EP or PPUL.18-19 FPUL was defined as a PUL with declining 
serum hCG levels successfully managed expectantly but there is no histological 
confirmation of the location of the pregnancy. IUP was defined as a visible 
intrauterine gestational sac TVS that did or did not contain a yolk sac or fetal pole. If 
products of conception were histologically confirmed after surgical evacuation, this 
was also defined as an IUP. EP was defined as a pregnancy where an IUP could not 
be visualized using TVS but one of the following was: an inhomogeneous adnexal 
mass separate from the ovary (‘blob sign’)12, an empty extra-uterine gestational sac in 
the adnexa (‘bagel sign’)20 or an extra-uterine gestation sac with a yolk sac, fetal pole, 
or fetal cardiac activity. If after laparoscopy or laparotomy an EP was confirmed 
histologically, this was also classified as an EP. Finally, PPUL was defined as a 
pregnancy that remained a PUL but with serum hCG plateauing and varying by <15% 
on three consecutive samples 48 hours apart. These are most likely to be EPs not 
visualized on TVS as the hCG levels behave in the same way biochemically. 
Therefore, PPUL were analyzed as EP, i.e. high-risk PUL.  
Two-step triage protocol for PUL 
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The aim of the triage protocol is to select a group of PUL as low-risk with high 
confidence, and classify most EP as high-risk. We developed a triage protocol that 
involves two steps (Figure 1). The first triage step classifies PUL as low-risk at 
presentation using a simple threshold value for serum progesterone. This is to reduce 
unnecessary follow-up for PUL that are very likely to have a final outcome of FPUL. 
Patients not classified as low-risk at presentation proceed to the second step that 
applies a risk model using the hCG ratio as the key predictor. Other predictors used in 
the model are the initial hCG and progesterone levels. We have called this risk model 
M6P. For patients using progesterone supplements, a variant of M6P can be used in 
which the initial progesterone is not included in the model as a predictor (M6NP). 
When using M6P or M6NP, we define PUL with an estimated risk of EP below 5% as 
low-risk.  
Using this two-step protocol, some PUL (likely outcome: FPUL) are classified as 
low-risk after the initial visit, and the remainder as either low or high-risk after the 
follow-up visit. Note that the risk model can also be used in isolation, i.e. without a 
first step based on initial progesterone. 
 
Sample size and statistical analysis 
Overall, data on 2753 women were available, see Results for patient flow. The triage 
protocol was developed on the first set of patients from each center (N=1449, of 
which 785 FPUL, 501 IUP, and 163 EP), and validated on the second half (N=1304, 
of which 665 FPUL, 501 IUP, and 138 EP).  
 
Missing values for initial serum progesterone and hCG levels at approximately 48hrs 
were handled using multiple imputation,21 see Supplementary Material for details. 
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Second hCG levels taken more than three days after the initial hCG were considered 
missing.  
 
For the first step of the protocol, a cut-off on initial progesterone was determined. 
Knowing that hCG ratio is in fact more predictive than initial progesterone, we aimed 
for a cut-off that limits the number of EP classified as low-risk based on only the 
initial progesterone level to a strict minimum.  
The risk model for the second step of the triage protocol is based on multinomial 
logistic regression. We considered initial hCG, the hCG ratio and initial progesterone 
as predictors, and used the method of multivariable fractional polynomials22 to help 
determine whether these variables have linear effects, and if not to help select the 
optimal transformation. Further, we considered an interaction term between the hCG 
ratio and progesterone. More information is provided in Supplementary Material.  
 
Validation 
The main performance measures were negative predictive value (NPV, percentage of 
non-EP among patients classified as low-risk) to assess the confidence of the 
classification as low-risk, and sensitivity (percentage of EP classified as high-risk) to 
assess how many EP are correctly selected for close follow up. Other important 
measures are the overall percentage of PUL classified as low-risk, as this is the group 
that would receive reduced follow up, and the false positive rate (percentage of non-
EP classified as high-risk). Performance was then compared with that of other 
available triage tools for PUL: M4-based triage (again using an estimated risk of EP 
<5% to define low-risk14), and a single visit protocol using a serum progesterone level 
of ≤10nmol/l to define low-risk.5  
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In addition, for M6P, M6NP, and M4 the AUC for EP (i.e. based on the estimated risk 
of EP) was computed, as well as a multinomial AUC to quantify overall 
discrimination between FPUL, IUP, and EP.23 Calibration curves were constructed for 
the risk of EP to investigate whether the estimated risks are correct.24  
Finally, we compared the clinical utility of triage based on M6P, M6NP, and M4 (with 
an estimated risk of EP <5% defining low-risk) using the Net Benefit statistic.25 Net 
Benefit combines results for sensitivity and specificity, while taking into account that 
the 5% risk cut-off implies that classifying an EP as low-risk is clearly worse than 
classifying a non-EP as high-risk. See Supplementary Material for full details. 
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Results 
 
A total of 3152 PUL were recruited during the study period, 2058 from SGH and 
1094 from QCCH. 162 PUL were lost to follow up (5.1%). We excluded 271 of 3152 
patients upfront: 58 from SGH that were lost to follow up on whom we have no 
information, 212 with an initial hCG ≤25IU/L, and 1 taking progesterone supplements, 
leaving 2881 patients (1858 SGH, 1023 QCCH). In the remaining group, there were 
164 missing values for serum hCG at 48hrs (5.7%) and 188 for initial progesterone 
(6.5%). Of the 164 patients with a missing value for serum hCG at 48hrs, in 62 the 
second hCG measurement was taken more than 3 days after the first and hence not 
used. For 128 PUL, the final outcome of the pregnancy was unknown (4.4%). These 
128 patients were discarded, leaving 2753 patients (1786 from SGH, 967 from 
QCCH).   
 
Of the 2753 PUL, there were 1450 (52.7%) FPUL, 1002 (36.4%) IUP, and 301 
(10.9%) EP. The EP rate was 9.5% at SGH and 13.7% at QCCH. The development 
dataset included data from the first 921 (52%) patients from SGH and the first 528 
(55%) patients from QCCH  (1449 in total). The remaining patients formed the 
validation data (1304 in total, 865 from SGH and 439 from QCCH). Descriptive 
statistics per center are presented in Table 1, and separately for development and 
validation data in Table S1. 
 
Development of the two step triage protocol 
First step. Based on the performance of initial progesterone cut-offs ranging from ≤2 
to ≤10nmol/l on the development data (Table 2; Figure 2a), we defined low-risk as 
having a serum progesterone ≤2nmol/l.  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Second step. The following variables were selected for the M6P model: log(initial 
hCG), log(initial progesterone), log(hCG ratio), log(hCG ratio) squared, and the 
interaction between log(hCG ratio) and log(initial progesterone). The M6NP model 
does not use log(initial progesterone) and the interaction between log(initial 
progesterone) and log(hCG ratio), although a joint likelihood ratio test for these two 
terms suggested that they had a strong effect (p<0.0001). 
 
Evaluating the triage protocol on the temporal validation set 
The selected progesterone cut-off (≤2 nmol/l to define low-risk) classified 210/1304 
(16.1%) patients as low-risk at the initial visit (Table 3; Figure 2b). In 206 of these 
210 cases the final outcome confirmed they were not an EP (i.e. FPUL or IUP) (NPV 
98.1%). Four of the 138 EP were classified as low-risk, yielding a sensitivity of 
97.1% (134/138). Finally, when only applying step 1, 960/1166 FPUL and IUP were 
classified as high-risk (false positive rate 82.3%).  
 
When all 1094 PUL classified as high-risk on the basis of step 1 were triaged using 
M6P as the second step of the protocol, an additional 600 (54.8%) were re-classified 
as low-risk, with an NPV of 98.8% (593/600), a sensitivity of 94.8% (127/134, i.e. 7 
EP classified as low-risk), and a false positive rate of 38.2% (367/960). 
 
Taken together, the two-step protocol classified 62.1% PUL as low-risk (810/1304) 
with an NPV of 98.6% (799/810), a sensitivity of 92.0% (127/138) (i.e. 11 EP were 
misclassified as low-risk), and a false positive rate of 31.5% (367/1166) (Table 3). 
When using the M6NP model as the second step, 57.7% PUL were classified as low-
risk with an NPV of 98.1%, a sensitivity of 89.6%, and a false positive rate of 36.6%. 
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Validation performance when using the M6P (or M6NP) model in isolation as a 
single step approach 
The M6P model in isolation (i.e. without the first step) classified 60.5% PUL 
(789/1304) as low-risk with an NPV of 99.1% (782/789), a sensitivity for EP of 
94.9% EP (131/138) (i.e. 7 EP misclassified as low-risk), and a false positive rate of 
32.9% (385/1166) (Table 3). The AUC for EP vs. other PUL was 0.903 (95% CI 
0.880 to 0.922) (Table S2, Figure S1). The M6NP model classified 54.5% PUL as low-
risk with an NPV of 98.6%, a sensitivity of 92.5% (128/138), and a false positive rate 
of 39.9%. The AUC for EP vs. other PUL was 0.870 (95% CI 0.837 to 0.897). The 
estimated risks of EP given by the M6P and M6NP models were accurate as indicated 
by the calibration plots (Figure 3), even when evaluated for both centers separately 
(Figure S2). 
 
Performance of currently available triage tools: M4 model and a single visit 
progesterone protocol  
The M4 model classified 70.6% PUL as low-risk with an NPV of 97.2%, a sensitivity 
for EP of 81.4%, and a false positive rate of 23.2% (Table 3). The AUC for EP vs. 
other PUL was 0.847 (95% CI 0.808 to 0.880) (Table S2, Figure S1), which is 0.056 
lower than the M6P model (95% CI 0.029 to 0.083), and 0.023 lower than the AUC of 
the M6NP model (95% CI 0.009 to 0.036). The calibration plots indicates that the risk 
of EP given by M4 was underestimated (Figure 3). The Standardized Net Benefit to 
assess clinical usefulness of triage at the 5% risk cut-off for EP was 0.71 for M4, 0.80 
for the M6P model, and 0.75 for the M6NP model. This is equivalent to an increase in 
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sensitivity of 9% for M6P vs M4 and of 4% for M6NP vs M4 at the same level of 
specificity.  
The existing single visit progesterone protocol (≤10nmol/l indicating a low-risk PUL) 
classified 43.8% PUL as low-risk with an NPV of 94.7%, a sensitivity for EP of 
78.1%, and a FPR of 53.6%.  
 
 
Updating the M6P and M6NP models using all data 
Finally, to make full use of all the available data after successful temporal validation, 
we updated the coefficients of M6P and M6NP using all data (n=2753). The final 
coefficients are given in Table S3, with additional information in Supplementary 
Material. 
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Discussion  
 
We have proposed a two-step approach to triage PUL using the initial serum 
progesterone level at the first step and a risk prediction model based on hCG ratio, 
with or without the initial progesterone level, at the second step. We have shown that 
this protocol classifies the majority of PUL as low-risk or high-risk with a high level 
of confidence. When an initial progesterone ≤2nmol/l is used to classify PUL as low-
risk at the first step, a significant proportion of women (about 1 in 6) with a PUL can 
be discharged following an initial consultation with just a urinary pregnancy test at 
home in two weeks as follow-up and minimal risk of misclassifying EP.  
 
A strength of the study is the large sample size and the inclusion of a temporal 
validation. As a result, the new M6P and M6NP models have better predictive ability 
(discrimination) and provide more accurate risk estimates than M4, which was based 
on a much smaller number of PUL.  A further strength is that the two-center nature of 
the study increases the likelihood of the protocol and models being applicable in other 
populations. The protocol is based solely on measurements of progesterone and hCG 
rather than more subjective information, therefore the approach is more likely to be 
generalizable. A weakness of the study is that serum progesterone levels were missing 
in 188 (6.5%) and serum hCG levels were missing in 164 (5.7%) patients. However, 
we used multiple imputation to deal with these missing values, which is 
recommended over the use of complete case analysis.21  
 
The advantage of incorporating serum progesterone as part of a two-step strategy into 
the algorithm is that a proportion of patients can be discharged at the initial visit. 
Using a relatively low cut-off value for progesterone means only 2.9% of EP will be 
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misclassified as low-risk at this first step. However, we advise these patients to 
undergo a urinary pregnancy two weeks later with telephone follow-up and to contact 
the unit in the event of pain or any other concerns they may have. It is an open 
question whether the cut-off value for progesterone as a first step test can be set 
higher. This will result in more women being triaged as low-risk, but at the cost of 
reduced follow up for more EP (Table 2). It can be argued these EP with relatively 
low progesterone levels are likely to be failing and resolve without complications. 
The concern is that there are insufficient data currently to accurately determine the 
safety of a policy of assuming such EP are low-risk and safe to manage expectantly. 
This issue was addressed by Cordina et al.5 In this interventional study, an initial 
serum progesterone level of ≤10 was used to define low-risk PUL. Of the 227 
classified as low-risk in whom there was complete follow-up, 14 women returned for 
unscheduled visits because of pain and/or bleeding. Five were subsequently found to 
have an EP. Three cases resolved without needing intervention. Two cases underwent 
laparoscopic salpingectomies because of pain, and in neither case was significant 
blood found in the pelvis. Clearly proving safety is difficult, however these data 
suggest that, using this protocol, the number of clinically important EP classified as 
low-risk is approximately 1%. We used 2nmol/l as a cut-off, because we felt this 
reached a sensible balance between the size of the group selected for minimal follow-
up (1 in 6 in our study) and the number of EP that are placed in this group. Given the 
lack of safety data, such a low cut-off seems warranted. 
 
The second step of our two-step protocol uses either the M6P or M6NP model. These 
models can also be used in isolation. As such, they perform better than previously 
suggested single-step protocols such as a serum progesterone cut-off value of ≤105,6 
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and the M4 model14 (Table 3). In fact, using the M6P model as a single-step protocol 
had higher sensitivity for EP than the two-step protocol (94.9% versus 92.0%). The 
two-step approach, however, benefits from discharging a proportion of women after 
just one visit.  
 
Using measurements of progesterone to predict early pregnancy outcomes is 
confounded by women taking progesterone supplementation, as this significantly 
raises serum levels. In these circumstances a low serum progesterone at the initial 
visit (step 1) can still be used to indicate a failing pregnancy. A limitation of the study 
is that our patient population was not suitable to perform a sub-analysis to investigate 
model performance in women taking progesterone supplementation, as progesterone 
is not routinely given in the UK. We only identified one patient taking progesterone, 
and this case was excluded from the final analysis. To deal with this issue we 
developed the M6NP model that does not use progesterone as a variable. However, as 
can be seen in table 3, the number of PUL classified as low-risk with this model is 
lower than when progesterone is included as a variable (52.6% versus 60.8% 
respectively). 
 
As urinary pregnancy tests become more sensitive and with the ubiquitous access to 
ultrasonography that exists in many parts of the world, the chances of pregnant 
women undergoing a scan that fails to identify the location of their pregnancy is 
significant26. This creates an iatrogenic problem that needs to be managed whilst 
ensuring that EP in women with symptoms are detected. The two-step protocol we 
have described offers an effective strategy for selecting low-risk cases where follow-
up can be reduced to a minimum, whilst directing resources to women at highest risk 
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of harboring an EP. We believe using the protocol will make the interpretation of 
serum hormone levels to manage PUL more straightforward, particularly in the hands 
of less experienced staff, out of hours or at weekends. We hope this will lead to more 
consistent decision-making and reduce the number of visits and interventions for 
women. We have made M6P and M6NP available as a free online application at 
www.earlypregnancycare.org. We have also incorporated the models into an 
application that can be downloaded onto smartphones or tablets, allowing clinicians to 
incorporate its use into everyday clinical practice. 
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TABLES:  
Table 1. Descriptive statistics presented as median (interquartile range) in the two 
participating hospitals. SGH = St Georges’ Hospital; QCCH = Queen Charlottes’ & 
Chelsea Hospital; PUL = pregnancy of unknown location; IUP = intrauterine 
pregnancy; hCG = human chorionic gonadotrophin. 
Center 
   Variable 
Failed PUL IUP Ectopic 
SGH N=898 N=719 N=169 
Age (years) 31 (26-36) 30 (24-34) 31 (28-35) 
Initial hCG (IU/L) 257 (87-742) 539 (280-982) 419 (198-1039) 
48 hour hCG (IU/L) 112 (37-326) 1212 (610-2052) 518 (221-1238) 
hCG ratio 0.40 (0.28-0.61) 2.18 (1.90-2.48) 1.18 (0.94-1.45) 
Initial progesterone (nmol/l) 5 (3-10) 68 (52-91) 23 (12-43) 
    
QCCH N=552 N=283 N=132 
Age (years) 33 (27-37) 31 (26-35) 33 (29-37) 
Initial hCG (IU/L) 425 (129-1726) 712 (322-1747) 480 (188-1139) 
48 hour hCG (IU/L) 180 (58-604) 1329 (635-2785) 550 (234-1409) 
hCG ratio 0.37 (0.26-0.52) 2.03 (1.36-2.44) 1.20 (0.98-1.54) 
Initial progesterone (nmol/l) 5 (2-10) 51 (31-70) 21 (11-32) 
SGH = St Georges’ Hospital; QCCH = Queen Charlottes’ & Chelsea Hospital; PUL = 
pregnancy of unknown location; IUP = intrauterine pregnancy; hCG = human 
chorionic gonadotrophin. 
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Table 2. Development data performance of different initial progesterone (measured in 
nmol/l) cut-offs to define low-risk at presentation. EP = ectopic pregnancy; PUL = 
pregnancy of unknown location; Prog = progesterone 
Progesterone cut-off 
to define low-risk 
PUL classified as 
low-risk 
Negative 
predictive value 
Sensitivity for EP  False positive rate
≤2nmol/l 200/1449, 13.8% 197/200, 98.5% 160/163, 98.2% 1089/1286, 84.7%
≤3nmol/l 293/1449, 20.2% 286/293, 97.6% 156/163, 95.7% 1000/1286, 77.8%
≤4nmol/l 377/1449, 26.0% 367/377, 97.3% 153/163, 93.9% 919/1286, 71.5%
≤5nmol/l 445/1449, 30.7% 429/445, 96.4% 147/163, 90.2% 857/1286, 66.6%
≤6nmol/l 505/1449, 34.8% 486/505, 96.2% 144/163, 88.3% 800/1286, 62.2%
≤7nmol/l 549/1449, 37.9% 526/549, 95.8% 140/163, 85.8% 760/1286, 59.1%
≤8nmol/l 583/1449, 40.2% 555/583, 95.3% 136/163, 83.3% 731/1286, 56.8%
≤9nmol/l 609/1449, 42.0% 579/609, 95.2% 134/163, 81.9% 707/1286, 55.0%
≤10nmol/l 636/1449, 43.9% 603/636, 94.9% 130/163, 79.9% 683/1286, 53.1%
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Table 3. Performance of PUL classification approaches. Confidence intervals are 
given between parentheses. EP = ectopic pregnancy; PUL = pregnancy of unknown 
location; Prog = progesterone 
Data 
   Classification approach 
PUL classified 
as low-risk 
Negative 
predictive 
value 
Sensitivity for 
EP 
False positive 
rate 
Development data     
Step 1 only:  
Progesterone cut-off 200/1449, 13.8% 197/200, 98.5% 160/163, 98.2% 1089/1286, 84.7% 
Two-step protocol:  
Step 1 + M6P model 
896/1449, 61.9% 884/896, 98.7% 151/163, 92.6% 402/1286, 31.2% 
Two-step protocol:  
Step 1 + M6NP model 
797/1449, 55.0% 783/797, 98.3% 149/163, 91.7% 503/1286, 39.1% 
M6P model in isolation 
 880/1449, 60.8% 871/880, 99.0% 154/163, 94.4% 415/1286, 32.3% 
M6NP model in isolation 
 762/1449, 52.6% 751/762, 98.6% 152/163, 93.4% 535/1286, 41.6% 
Validation data     
Step 1 only:  
Progesterone cut-off 
210/1304, 16.1% 
(14.2-18.2) 
206/210, 98.1% 
(95.0-99.3) 
134/138, 97.1% 
(92.4-98.9) 
960/1166, 82.3% 
(80.0-84.5) 
Two-step protocol:  
Step 1 + M6P model 
810/1304, 62.1% 
(58.8-65.3) 
799/810, 98.6% 
(97.5-99.3) 
127/138, 92.0% 
(85.9-95.6) 
367/1166, 31.5% 
(28.1-35.0) 
Two-step protocol:  
Step 1 + M6NP model 
754/1304, 57.7% 
(53.2-62.1) 
740/754, 98.1% 
(96.8-98.9) 
124/138, 89.6% 
(83.0-93.9) 
426/1166, 36.6% 
(32.0-41.5) 
M6P model in isolation 
789/1304, 60.5% 
(57.1-63.8)
782/789, 99.1% 
(98.1-99.6)
131/138, 94.9% 
(89.4-97.6) 
384/1166, 32.9% 
(29.5-36.5)
M6NP model in isolation 
716/1304, 54.5% 
(49.8-59.2) 
706/716, 98.6% 
(97.3-99.2) 
128/138, 92.5% 
(86.4-96.1) 
460/1166, 39.9% 
(35.0-45.1) 
M4-based triage 921/1304, 70.6% (68.0-73.1) 
895/921, 97.2% 
(95.9-98.1) 
112/138, 81.4% 
(73.9-87.2) 
271/1166, 23.2% 
(20.8-25.8) 
Single visit prog ≤10nmol/l 572/1304, 43.8% (41.1-46.6) 
542/572, 94.7% 
(92.5-96.3) 
108/138, 78.1% 
(70.3-84.3) 
625/1166, 53.6% 
(50.7-56.5) 
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Figure 2: Scatter plot with the cut-off for step 1 of the two-step approach. Panel A is 
based on the development data, panel B on the validation data. A cut-off of ≤2nmol/l 
is used for the initial progesterone level to classify PUL as low-risk. Failed = failed 
PUL; IUP = intrauterine pregnancy; hCG = human chorionic gonadotrophin. 
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